|
Antineoplastic Agents - Antineoplastic And Immunomodulatory Agents. Part No. 1 L01aa01 Cyclophosphamide For Parenteral Administration,Part No. 2 L01aa03 Melfalan For Parenteral Administration,Part No. 3 L01aa06 Ifosfamid For Parenteral Administration,Part No. 4 L01aa09 Bendamustin For Parenteral Administration,Part No. 5 L01ac01 Tiota For Parenteral Administration,Part No. 6 L01ad01 Carmustin For Parenteral Administration,Part No. 7 L01ax04 Dakarbazin For Parenteral Administration,Part No. 8 L01ba01 Methotrexate For Parenteral Administration,Part No. 9 L01bb04 Kladribbin For Parenteral Administration,Part No. 10 L01bc01 Cytarabin For Parenteral Administration,Part No. 11 L01bc02 Fluorouracil For Parenteral Administration,Part No. 12 L01bc05 Gemcitabin For Parenteral Administration,Part No. 13 L01bc07 Azacitidine For Parenteral Administration,Part No. 14 L01ca01 Vinblastin For Parenteral Administration,Part No. 15 L01ca02 Vincristin For Parenteral Administration,Part No. 16 L01ca04 Vinorelbin For Parenteral Administration,Part No. 17 L01cb01 Etoposide For Parenteral Administration,Part No. 18 L01cd01 Paklitaxel For Parenteral Administration,Part No. 19 L01cd01 Paklitaxel In The Form Of Nanoparticles Bound To Albumin For Parenteral Administration,Part No. 20 L01ce02 Irinotecan For Parenteral Administration,Part No. 21 L01ce02 Pegylated Liposomal Irinotecan For Parenteral Administration,Part No. 22 L01cx01 Trabektedin For Parenteral Administration,Part No. 23 L01db01 Doxorubicin For Parenteral Administration,Part No. 24 L01db01 Liposomal Doxorubicin For Parenteral Administration,Part No. 25 L01db01 Liposomal Pegylated Doxorubicin For Parenteral Administration,Part No. 26 L01db02 Daunubicin For Parenteral Administration,Part No. 27 L01db03 Epirubicin For Parenteral Administration,Part No. 28 L01db06 Idabicin For Parenteral Administration,Part No. 29 L01db07 Mitoxantron For Parenteral Administration,Part No. 30 L01dc01 Bleomycin For Parenteral Administration,Part No. 31 L01dc03 Mitomyycin For Parenteral Administration,Part No. 32 L01fg02 Ramucirumab For Parenteral Administration,Part No. 33 L01xa01 Cisplatina For Parenteral Administration,Part No. 34 L01xa02 Carboplatin For Parenteral Administration,Part No. 35 L01xa03 Oxaliplatin For Parenteral Administration,Part No. 36 L01fa01 Rituximab For Subcutaneous Administration,Part No. 37 L01fa01 Rituximab For Parenteral Administration,Part No. 38 L01fd01 Trastuzumab For Subcutaneous Administration,Part No. 39 L01fd01 Trastuzumab For Parenteral Administration,Part No. 40 L01fx02 Gemtuzumab Ozogamicin For Parenteral Administration,Part No. 41 L01fe01 Cetuximab For Parenteral Administration,Part No. 42 L01fg01 Bevacizumab For Parenteral Administration,Part No. 43 L01fg01 Bevacizumab For Parenteral Administration,Part No. 44 L01fe02 Panitumumab For Parenteral Administration,Part No. 45 L01fx05 Brentuximab Vedotin For Parenteral Administration,Part No. 46 L01fd02 Pertuzumab For Parenteral Administration,Part No. 47 L01fd03 Trastuzumab Emtansin For Parenteral Administration,Part No. 48 L01xc15 Obinutuzumab For Parenteral Administration,Part No. 49 L01ff01 Nivolumab For Parenteral Administration,Part No. 50 L01ff02 Pembrolisumab For Parenteral Administration,Part No. 51 L01fc01 Daratumumab For Subcutaneous Administration,Part No. 52 L01fc01 Daratumumab For Parenteral Administration,Part No. 53 L01xc26 Inotuzumab Ozogamicin For Parenteral Administration,Part No. 54 L01ff04
|
